NCT03533439

Brief Summary

Gastroschisis is one of the most common neonatal surgical conditions, and is increasing in incidence. Postnatal bowel ischemia leading to necrosis, bowel loss and short-bowel syndrome, occurs in a few instances, with significant impact. Intestinal gangrene occurs in up to 37%. The cause of the gangrene can be multifactorial. Contributing factors can be volvulus; venous engorgement with ensuing arterial compromise; constriction of the gut mesentery at the defect; and contribution of the hydrostatic effect of the column of bowel within a silo. Theoretically, the increased hydrostatic pressure incurred by the bowel in a preformed silo, may decrease blood flow to the apex of the bowel and contribute to ischemia. However, this does not seem to be the norm, as most cases do well in the silo. Cases of intestinal ischaemia within the silo have been described in patients. Any objective measure of bowel perfusion and therefore viability which can aid clinical assessment and management may benefit patient outcome. Near-infrared spectroscopy (NIRS) is used to noninvasively measure and monitor changes in the approximate regional haemoglobin oxygen saturation (SO2) in the blood. Measurement of oxygen saturation using NIRS is already in clinical application in other neonatal and paediatric medical and surgical diseases. NIRS has been recommended as a good trend indicator of changes in neonatal tissues oxygenation. NIRS-measured duration of cerebral oxygen desaturation is an accurate predictor of postoperative neurological injury in children undergoing cardiac surgery. The investigators propose to use NIRS to measure SO2 in the intestinal bed in patients with gastroschisis and to ascertain if there is any clinical advantage to routine monitoring in these patients. The aim of the study will be to:

  1. 1.Measure Gastrointestinal SO2 (GSO2) of the bowel within the silo of gastroschisis patients
  2. 2.Identify the clinical progress of patients with gastroschisis in the postnatal period
  3. 3.Identify any association of the measured GSO2 with the clinical outcome and any gastrointestinal complications

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2013

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2013

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2017

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

April 23, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 23, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

September 23, 2024

Status Verified

January 1, 2018

Enrollment Period

3.9 years

First QC Date

April 23, 2018

Last Update Submit

September 20, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • The incidence of intestinal ischemia requiring intervention and its correlation to measured GSO2

    Through study completion, an average of 6 weeks

Secondary Outcomes (2)

  • Time to full feeds

    Through study completion, an average of 6 weeks

  • Changes in renal oxygenation measured by near infra-red spectroscopy

    Through study completion, an average of 6 weeks

Interventions

Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management

Also known as: in-vivo optical spectroscopy oximeter; INVOS (Somanetics, Troy, Mich).

Eligibility Criteria

AgeUp to 14 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Newborn babies at neonatal unit

You may qualify if:

  • Gastroschisis diagnosed antenatally or at birth

You may not qualify if:

  • Associated congenital condition affecting respiratory system , cardiovascular system or global development
  • Generalised sepsis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Gastroschisis

Interventions

Spectroscopy, Near-Infrared

Condition Hierarchy (Ancestors)

Musculoskeletal AbnormalitiesMusculoskeletal DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHernia, AbdominalHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Diagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisSpectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Merrill McHoney, PhD

    NHS Lothian

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 23, 2018

First Posted

May 23, 2018

Study Start

October 15, 2013

Primary Completion

August 31, 2017

Study Completion

July 1, 2018

Last Updated

September 23, 2024

Record last verified: 2018-01